0001564590-21-048719.txt : 20210923 0001564590-21-048719.hdr.sgml : 20210923 20210923162149 ACCESSION NUMBER: 0001564590-21-048719 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210921 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210923 DATE AS OF CHANGE: 20210923 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AGILENT TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001090872 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 770518772 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15405 FILM NUMBER: 211272772 BUSINESS ADDRESS: STREET 1: 5301 STEVENS CREEK BLVD CITY: SANTA CLARA STATE: CA ZIP: 95051 BUSINESS PHONE: (408) 345-8886 MAIL ADDRESS: STREET 1: 5301 STEVENS CREEK BLVD, MS 1A-LC STREET 2: P.O. BOX 58059 CITY: SANTA CLARA STATE: CA ZIP: 95052-8059 FORMER COMPANY: FORMER CONFORMED NAME: AGILENT TECHNOLOGIES INC DATE OF NAME CHANGE: 19990816 FORMER COMPANY: FORMER CONFORMED NAME: HP MEASUREMENT INC DATE OF NAME CHANGE: 19990716 8-K 1 a-8k_20210921.htm 8-K a-8k_20210921.htm
false 0001090872 0001090872 2021-09-21 2021-09-21

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 21, 2021

 

AGILENT TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-15405

 

77-0518772

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

 

 

5301 Stevens Creek Boulevard, Santa Clara, CA

 

95051

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (800) 227-9770

  

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐          Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.01 Par Value

 

A

 

New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐ 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 


 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(d)On September 21, 2021, the Board of Directors (the “Board”) of Agilent Technologies, Inc. (the “Company”), upon the recommendation of its Nominating/Corporate Governance Committee, increased the size of the Board from 10 to 11 members and appointed Dr. Mikael Dolsten to fill the vacancy so created, both effective September 21, 2021. Dr. Dolsten was appointed to serve in the class of directors that will stand for re-election at the 2022 Annual Meeting of Stockholders. Dr. Dolsten will serve on the Audit and Finance Committee and Nominating/Corporate Governance Committee of the Company’s Board.

 

Dr. Dolsten, age 63, has served as Chief Scientific Officer, President, Worldwide Research, Development and Medical of Pfizer Inc. (“Pfizer”) since 2019. He served as President of Worldwide Research and Development of Pfizer from December 2010 to December 2018. He served as President of Worldwide Research and Development and Senior Vice President of Pfizer from May 2010 until December 2010 and President of Pfizer BioTherapeutics Research & Development Group and Senior Vice President of Pfizer from 2009 until 2010. From 2008 to 2009, Dr. Dolsten served as Senior Vice President of Wyeth Pharmaceuticals, Inc., a public biopharmaceutical company that was acquired by Pfizer in 2009, and President of Wyeth Research from 2008 to 2009. Prior to joining Wyeth, Dr. Dolsten was a Private Equity Partner at Orbimed Advisors, LLC and Executive Vice President, Head of Pharma Research at Boehringer Ingelheim, a pharmaceutical company. Dr. Dolsten also previously held research leadership positions at AstraZeneca plc, Pharmacia and Upjohn Company. Dr. Dolsten has also served on the board of directors of Karyopharm Therapeutics Inc., a public pharmaceutical company, since March 2015 and the board of directors of Vimian Group, a company supporting veterinary professionals, since April 2021.

 

The Board has determined that Dr. Dolsten meets the independence standards adopted by the Board in compliance with the New York Stock Exchange corporate governance listing standards and Item 407(a) of Regulation S-K.

 

Dr. Dolsten has (i) no arrangements or understandings with any other person pursuant to which he was appointed as a director, and (ii) no family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer.

 

Dr. Dolsten has had (i) no direct or indirect material interest in any transaction or series of similar transactions contemplated by Item 404(a) of Regulation S-K and, (ii) as of the date of this Current Report on Form 8-K, Dr. Dolsten holds no direct or indirect beneficial ownership in the Company’s stock or rights to acquire the Company’s stock.  In the ordinary course of business, Agilent sells products and services to Pfizer.

 

Dr. Dolsten will receive the standard compensation, a portion of which will be pro-rated to reflect the actual time Dr. Dolsten will serve on the Company’s Board this year, paid by the Company to all of its non-employee directors and as described under “Compensation of Non-Employee Directors” in the Company’s Proxy Statement for its Annual Meeting of Stockholders filed with

 

 

the Securities and Exchange Commission (“SEC”) on February 4, 2021. In connection with his appointment, Dr. Dolsten will enter into a standard indemnification agreement with the Company in the form previously approved by the Board, which is filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 10, 2008 and is incorporated by reference herein.

 

Item 7.01.Regulation FD Disclosure.

 

The Company issued a press release on September 23, 2021 announcing the appointment of Dr. Mikael Dolsten to the Company’s Board. A copy of the press release is furnished as Exhibit 99.1 to this report.

 

The information in this Item 7.01 and Exhibit 99.1 attached hereto are intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release, dated September 23, 2021, announcing new board member.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 


 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

AGILENT TECHNOLOGIES, INC.

 

 

 

 

 

By:

/s/ P. Diana Chiu

 

Name:

P. Diana Chiu

 

Title:

Vice President, Assistant General Counsel

& Assistant Secretary

 

 

 

 

 

 

 

Date: September 23, 2021

 

 

 

 

 

 EX-99.1 2 a-ex991_44.htm EX-99.1 a-ex991_44.htm

Exhibit 99.1

 

Dr. Mikael Dolsten Named to Agilent Board of Directors

Pfizer executive brings strong scientific and medical expertise to Agilent board

SANTA CLARA, Calif., Sept. 23, 2021 – Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Mikael Dolsten, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer Inc. has been elected to Agilent’s board of directors, effective Sept. 21, 2021.

Dr. Dolsten brings 30 years of pharma experience to the Agilent board. During his career, he has led teams that have selected more than 150 candidate drugs entering human clinical studies for the treatment or prevention of human disease and has been involved in advancing more than 30 drugs and vaccines to approval. Most recently, he co-led Pfizer’s recent collaboration with BioNTech to develop COMIRNATY® (COVID-19 vaccine, mRNA).

“Mikael’s outstanding scientific, medical and research background makes him a valuable addition to the Agilent board,” said Mike McMullen, Agilent president and CEO. “His leadership in small-molecule medicines, biotherapeutics, gene therapies and vaccines will be a key asset for Agilent moving forward. We look forward to working with Mikael and benefitting from his experience in these strategically important areas.”

“We’re pleased to welcome Mikael to the Agilent board,” said Koh Boon Hwee, chair of the Agilent board. “His deep background in pharma and successful leadership of critical research initiatives at Pfizer will add an important perspective to our work at Agilent.”

Dr. Dolsten has served in a variety of roles for Pfizer since 2009 including chief scientific officer, president of R&D and senior vice president and division president, Biotherapeutics Research and Development. He has served in his current role as president of Worldwide Research, Development and Medical since 2019, where he leads a team of over 8,000 scientists and oversees all global research operations across six therapeutic areas for Pfizer. In addition, during his career, Dr. Dolsten has served in research leadership positions for Wyeth Pharmaceuticals, Boehringer Ingelheim, AstraZeneca and Pharmacia & Upjohn.

He has published more than 150 scientific articles and book reviews and is an active leader in the scientific community. He currently serves as co-chair of the National Institutes of Health

 

 

(NIH)-Accelerating Medicines Partnership program and an executive committee member of the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative coordinating a national science strategy in response to COVID-19. Dr. Dolsten also serves on the Science and Regulatory Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He has been an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council and was recently elected as Foreign Member of The Royal Swedish Academy of Engineering Sciences.

Dr. Dolsten has served as an advisor to the Obama administration for regulatory sciences, to then Vice President Joe Biden in the Cancer Moonshot initiative and to the UK Government for the 2021 G7 Summit.

He is a member of the board of directors for Karyopharm Therapeutics, as well as the board at Vimian Group.

Dr. Dolsten received both his medical degree and doctorate from Lund University in Sweden where he was also selected as an adjunct professor in immunology.

 

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

# # # # #

Media Contact:

Tom Beermann

+1 408 386 5892

tom.beermann@agilent.com

 

 EX-101.SCH 3 a-20210921.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 a-20210921_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 a-20210921_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 a-8k_20210921_htm.xml IDEA: XBRL DOCUMENT 0001090872 2021-09-21 2021-09-21 false 0001090872 8-K 2021-09-21 AGILENT TECHNOLOGIES, INC. DE 001-15405 77-0518772 5301 Stevens Creek Boulevard Santa Clara CA 95051 800 227-9770 false false false false Common Stock, $0.01 Par Value A NYSE false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Sep. 21, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 21, 2021
Entity Registrant Name AGILENT TECHNOLOGIES, INC.
Entity Central Index Key 0001090872
Entity Emerging Growth Company false
Entity File Number 001-15405
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 77-0518772
Entity Address, Address Line One 5301 Stevens Creek Boulevard
Entity Address, City or Town Santa Clara
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95051
City Area Code 800
Local Phone Number 227-9770
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 Par Value
Trading Symbol A
Security Exchange Name NYSE
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports a-8k_20210921.htm a-20210921.xsd a-20210921_lab.xml a-20210921_pre.xml a-ex991_44.htm http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a-8k_20210921.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "a-8k_20210921.htm" ] }, "labelLink": { "local": [ "a-20210921_lab.xml" ] }, "presentationLink": { "local": [ "a-20210921_pre.xml" ] }, "schema": { "local": [ "a-20210921.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "a", "nsuri": "http://www.agilent.com/20210921", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "a-8k_20210921.htm", "contextRef": "C_0001090872_20210921_20210921", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "a-8k_20210921.htm", "contextRef": "C_0001090872_20210921_20210921", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.agilent.com/20210921/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001564590-21-048719-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-048719-xbrl.zip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

JFP#W M2"#^A/QVC$JD;BT0PZTBJ9 D\1"'PBPI/7S L]*E$7R&VA M7CE),T>=U<"F:RN#XUW", MB*PYA'CD:*+O1SC/=%-U]%4=W0^JCCH,!LM>N MI@N^0QPS_Y(:%ED/NYOB1P'DAE7/ S8]@ =Y?4-F2]^$-%XT"R Q7/0&I,&B M:V0CV*RS:1 F4(Q#&KDD3R&<1U1$@;IPB<4%FL %"3;+%+)S6.,&@EJF7$0" MH+[)0UPL!K(W0>'9"CAEW^@59:7J'6,\>1D M.)C35D%G-UN@:J\64WFD-DZ(.E]'9<&^D_%:,C@2;,'#E;:TEL'KS#V+:$#, M T(B()D^N:\%;=9_SKU,%9![20'R<$L-<0O78W*', \UXD,,KZW"V3SV#TQCFY_?+S92"W[_#6I%9GA"V"$HJ:=DLAN>2P5:Y6IAC:BDFIYFKHHO]UGJ"4O5R^-:YV;3 M.@.VPPMFQ ,D4?A4:?^!+;:";57).MG7+ZNE%3>QQ[]'4ZSV$C2X@;/2B=;W M;;+#SV+M;(/_2@,4S_[37.@"VZ:0;8J3^F+O]UXP6WB%VT 3<_!RAO@4T^GO MG#T'CP,VFT-:\6X[!Z))/K20.YN8"1N(Z$#,9\L$+;:(E=3-4CM(,R=,3($K M3-#-8C9&O%KNT_V:J/N*L[.$*PH0<=B2:HWJK$@5FQ0FU<4U$=0A]1B?,Q[^ M#6\4R/W9@"WD:K$:,+_B]FD+5!.Q"Z%WEO ,ZWL0\@+&0D7R[8K?*665B(CW Y="7^RP\P=$?Q.M<_G-!FAB1 [JS:2/Y0);0LF5B MFU6LM'K6VD*:.F)B2IS[OJQ=Q#^N,47=:M-!"]!$?:?W6(C MV%:-K!.=U-.[69Q'C& /!YA.O\@--\>0E,VRKF<]33>1S*?XE0,D)/N/<('X MK%@:NX0F-31N%ML[CM3\0%+>\#W%ZB,G_'8R*;]Q*$*HIVX^HODX2R['2Y&! MB V$=/L/=@E[6#G1[+2"O+@ !M5=,!K]H1 +Q)M/ V.$>TW<'_ 9(@X[9X3 M^;[I9T:.CC9[E#=+*MG3<'N#O(7<3ZVZO?$##DCI9QR;_6JNN&LXYL,?P@(V M =W>V_$[D!#N/^^YTK,B:6R2.=G6O(*#$'U787W@4/W7CM%J-F:EM^%KG>KI MEP'9048C>!#A[S^:>J%9KA;6B$JJZ6GFVGFY]![E0%&5#V3H^S:;W&FL'=P@ MQBP@H;'D QF%+K!M"MFF.*DD=OK$M3Q2_U'V[WL<"(&!S, L MJ2J%!R#)N7S^?')\CI/K+XN(HQE5FDG1L'S'LQ 51(9,C!K65-M8$\8LI&,L M0LREH UK2;7UY?.//US_9-OH]K[UB)HD9C-ZRS3A4D\5_=![^(B^_M9MHS83 MSP.L*;J59!I1$2,;C>-X4G?=^7SNA$,FM.33&+QKA\C(1;:=FKY1%)L+Z!;' M%"6?.JIX%=_V KOB]?V@7O/J7N $%Y<75[7+7SPX\K8,_+4:%MKZU-&%XSF^ M\RD(M@0[F#SC$46MVRU!\FGHA>'E)7R16N@-,*G5JM6+:N -AU?DJK:-5$Z6 MBHW&,?I /B808;Q"4,[I$MTS@05AF*->.M)?44L0!S4Y1UVCIE&7:JIF-'36 M5CGP5N3!'0B>'#6N+O<5 <4>JD5OQO*J;2EMK\<6>_+R:2/M!$+C)U8VH M9H<$P:SO?GUH]\B81MB&J8(H(,:!9G6=G&Q+DLS1$;A0KH0YLE,QVYRR_8I= M]9V%#BU@ Z$5'TIRVJ5#9'[_[+9V?.(1XQ!>20R9"?""BN\:0;=/HPF'"&JO M!IQ8&BLZ;%C83B6-IY\/"<;+"42\9G %QNU^#Y@8+Z20T7*%*KT?TM^F".]$ MS.)E2PREBA)27T7;!2O?3K&2/Y2)@N@3<2)M!K^C0!4-ZP\G7=<\+K*VP2;&\9#20_%M<+I;,"2L?L5P9]%O.3N&L$GTS#&&1T1T))03_ATU. ?>:A>*@]F ] MI$^JH^2,K8J>T\'NV2@.KIG!)]67<_$NI-OJQ8%<_T"-0?UWP=PU4 #0/EZT M0LBX;+A.&J?=VF\8*0 P-!)23:1*_"3Q=B.G(E;+T^^P-TP5 /X>*L?W$+RM M5P"LNXBJ$2QLORLYC\>PADRP6)Z&,,=$ 6!O(- 4YBVH$!9_T!-A[BD7 +!+ M1TR#%Q&?4H4?UCTKO+0;Z4#U(J$A"(DXJZ :EN]YON=XGH4F$'>F]6I8%0M- M-8"1$P/;U.$P#&@5% W;JW'GPDPP0O6N:2+Y?Z;C15QG?%3+R4=. LIXN2@G M+X<7CHR6RS+3LK?>9[P$9>8EIUS;L..7-.GNE]L9)27-NT?U2AE+I<["N8UP MQD^IT_'!78V,FU*GY ,;4QMF*J5.QWF;BQD]I4[-AS>*,W)*FI%WM_@S.DJ: M@/T]:W/BN):?=ZOV/V@S=Z:26C VCR20=-]*$[J'ZNXD%3*/O5^FA"U T\;V ME>PD[*_?\-W>U$X*!_O_?/]?_WGZ7^7R^3\8_>"G-DAOV7G7-JN+R/!]GM?#TC7 M<[G'R)\?KK^0<]^.QLP+29F,PC!H52IW=W>&,^">]-THA'&D8?OC"BF7DX[; M@E$L(.NVP^3^FV3+-3 >_ZPF0 MS+\6:1BF81F'S6:FXA6UO]$A(]WS3$7[<& ZSM$1_,>N.V:?VO5ZK=:H-K9G+JDE\RT!*BQ#7+FNN0: MFTERS203M\PQXEY'(:P K((G6_=]X?)W>QFLX1?#%\-*U31K%F6L M= ELXVA?UO!$M4@K2K"13"E144CB+"P05%5;B^ MA=LY4#S*;5E<517E*K-[>U1<%TMR59U0S$PQM_Q07,%B;&,BZ)F6C!>/ 06Y M(>Q("&#M27'MI#3?Q(^\4"QJH0OS,_:B<;6((*LFS#EDGN1]EY6Q&A.*Y66Y MBC(G)FB0(M]R&+BKJ0ZL9K-94:4IQ85B(:99U^?VB$2SD1&V:R6JX>93LI );F. M$JIYK)_C*5#+JX/_'+*1*VY39OR-^^VZO[7M ;6'Y!N:X1VS] MZ]U>"$184:U)!=N%/'09_$'+Q]_^2B2A 16@K)(4GE:285 #7'P")>"!Q@R9 M(+>H8ZI&(]%%?=^9O#]U^"V1X<1E[_8<+@.73G !&4+\'Z?\OH7=,8&_]$_N M.,Q3/]5OJ'NA5X5PY]W>Q[],_ =8\>@8NV2\=08*UD$E^]&EPWA^]^$U&\#, ML3K,PSP^JJ932O_8>S^@KF2GE=PXCXU=SX[=\0 QDS8,+JC;]1QV_YE-EH-A M6EH$B/J600K")=B H7QB,H85^;8E%7/!D$3)AA92]+L]R<>!BYRFOHT$0D3+ MZ>K>2R:*A/./:T D^/_ M@X33QU0,N5?N^V'HCUMF$)[$7T(_4#^Q;] #B)Z6^?/) $8K2_Y_K'4(A7OO M?_G).C1/3BO! [T>)MU0EP^]EC)$3_J^ )B2*N=^!!J6U*!F0!TTXY,2:PF0 M&E"H?MTQ'*/5]UU'?QC0,7F?/]J]G%Y\ZI'WY]6NWU^M>7KSN_,U5SO\/ M*D= >:'OE$:+5( MB%XIZ[.C+=.EI"G1_O*[/?"Q6PZT'D/;D4,G$P".>;CV 7SL@^E>M4HJ0/F8 M\'VAAJDA<34FW>![]F0RZQW_ "2I;3RF>?NE]0[M]TVK]>7'ZY M_ 26:8ET+]K&:]++T_CX!0EFOW-/01(B)I&C18I!0B61 ;/1@RVQ5S)Q*;U^+AN@ ,= &$6O4;N2[_; \K.9Z\J VFH?*/X=.Y3J=]Q/ M['S:ONO20+)6\L<)(3%*<(R6:=2J/Y_<<2<>LY-#7[GUQL_ MK$UW+18@1_,"I.O9O@ EI@*PO1#425L']=N^\WR]A+%?#-2$+!#^+8Z)BNF< MN?0.=%21>#FMA,X,(6CDOS8MK'CE5[GP4T[/8!/8$9@8T G:8\=B*V>QPWD6 M^\A=!C7!(%LV1&Z5K4;=;.SXY17Y9<1XWD>N:'WW7C7P%:JZ#D,:3&ME0&!LQ0]'X'_^'0DN':XB+ULIM)XNHU9B MT/](:GY-%-WVQV,NY8Z 5TW .Z)].:+M7O=(9QRX_H2)G>I[%9S[ \*SKO3! M3ESL]-W;(V/T58FVO7<4O%-X;X1J\ZXCN?"-@X?47I'L&'/'P8S!HH4PYY;! MG%D$I/$]'PL/(6_ MMDK*;58XK3D?3CMS',&DC/_WA7O,6BZ4UJB9%NF%F.4@\6P6^T8^^)'+ "YG M-KA66IS[8)D+86O#GY?BQK_SEH.L!VBAI.U209++U-_+[9,!N%&4D_K#I94Y0H7DI, M@@D$B#X>4)>P>V9'>+P7/H-!S>3.#=P%,MXB=8-L(BBO_2)WC6 MEM6U'8EYTUS&7WXZKEI')Y*$S&7!"-H03\6D2AAD=2.D:T(%H\ ]#B.GR$ ) M"N;4*-#"8@V72ZE$D_0,>EU>IQV;YJQ&.WC &,T=IOSBV]2]PDD^9\^[6CTJ M-X^.YH8_K2!25IJYN1Z2WT+"W_\(?S$1IZ0*E4@'/ZG6ST#S Z)3^!TBT44A M+I5)[KFQ+9FI+P#_JR]<>\3L;WARA- @$#Y849C^T/?O29^Y_ATN'!;B\I+C M\FN /P4,@"DPXB+PXE"V_+P.W[_MNGP(UA$"3B,GF4;U^,J@]JTC MTOYX3:HUTX"*!PNTY8Y)-H!)60Y[!&U/LD'&, MGGG&L.JT;%4SO)$[()AR1MTT=,T=CA\TYX>+6U>M M:J/:7*=3FC%UM9?(!/B9P?Q=",12LBWV&F$YYIS$YR%GT5H\FF!P/+].KWI> M50?'+=-<=#1U9L]#UZ\=J\.L)'\)DP13S"&F<=0(0O*3ODQES;N(1ZO<1+S! MF_+T#0GVB-@NE?)I&T'TRN*D9=XU'<_0CT)R@R M^@O$A3=WCMI=INII+"8W5MM9L2UY? M]&RBU2IQN_&_)-%F5=V.8FI\4#T4XR<3=MENC5>)X#VA@BALV!1%X9 M9P/5#YW":,SG2B?C?5+#M?5HKQ)57A3:38/+T]5\Q5CK&R*5[N !*8!9B(4B MA<\EYXQ 8#"7V2$(#,]7T==(,E6+W2_W?4D;15TD_P#ZU*C? MAY.1F*:>#UFY+QC]5J8#4"DMZM[1B8P?3ME$8;'\&<;O'C(;E(DW26)SN8@6 M5A&CZ89LC"^=57,,F+6U&W4UZW,64!%&0D5TSKD 6> +B2*ES41(P:"Y5&<^ MA/SEIT;SA'3<6%IDJ^NBLR#PN1>J34 H+6Z/&H]YDD*S"3D3 F4,MI!%38S' M,Y;_CF3(!Y,5[3X]2!K?"\61<=C\^3OIXR4SCIV#A<12TUP9+\>E1^;ODRXI MM?'!!SV3)Z5]_([9^U7S1!6KOZT3I6K.])-SY(:!OP.8&()M&S^.EVT7VTE) MRQ*) B!!K5?UYK.3IL+B#;T7_A@4(2J_2CN^?X613_XM$Z@>&5$W.(4A8^KP M $@SU)W8':(^48%Z+@/ACXEEHJ*T+#)6DT9WP,'\7J1W:'DN#/*5?Z/,)>>^ M*S$5$:H/N.NJCFZI#:-.B/0)C@4M2N!7@P)G@P%3[R86X--0O2;=W8'-,!T/ M$X3QM4#T-W M;6&8#LIUL,1#<%* B4]E?F@V!EEK OE&)+&*E*SCPO HOA M*V/*7(!^E**@0HA\ZS&!7?7WR6B1XSRRV.O"A MUF'.<]D.&6!ND #(OR2"GM4(N?LEKE^H'0($L]7AD:UBZ1Q-0"L MB%@VQ')!?TL%BCX)436MID%^91EXTE&QH_EQU5#9H:?#*?8_9W;,G*:6!-D/ MQ]\Y%O[N,8\#@_X..,JWST+QE4XT &C6NS- 82]%+3]P_V;$! U8%');3L'X MY:?:\4D.$'!)H^#IX."+BC$H"(%!/L9?CQ%#6%K*28XIAA9V_\>$@52\&E&@ M2%L!3-U8'0"E@=/2=X&6^MP/,CQ6. M"C&3E^& 5!]<07 9]>F2$7,=4 YQYZYZS$R.>$ "7_N@$D<\0_?U7\QC-HSB MVJ5DG3A5L_@M^-L?>8GPS@^(PD$-&M- K#GZB;$P55OPXS,5$[W )$>Y,U10 M/-%2+ .^JJG@VY$*N,6C_<['( 8U[6/O"2G)*,"C5+C8MPS3ICT "_WG 5,W M/RK"U&.=!4+Q .KLK398-TE9W:0&VDC%7V&)QBH$JV1 EOC&8-9(10$XC0#C M*[AJTZ (=?P@U+)B:O9Q3T=;N+)15+@%"Q?$XHF=6C;#J67CL(@>?7Z*Y&;CI,T05AF+V 0,Z8R MUL'_Q5!YVN)&02N(/?(ES#0F[J0!P-M'SXEE@"L<:4>0KTZ0(^HD1*F7!A<& MH\OJ[_00#Y*7P&>G0%2I)<7!:!R<$:AJ<9\("$6"BG.IR%:0>L,!Y!N-)1]* M)8WJNEDO%$U(NB5-NU0F!.C$;V"I7::V>BP\3![(@F;)*=>\J82.I5PPO3X8 M&$!X.$'_SHOMD-C-G74,I9+!Z-CB6D@DZMCP6US=R*6[9SV>/#W@%J'JQ1>. MUOVV#\RN)MN/0/&K4]A)^$)BFC%:!TYDAUK,HZF#=Z4@5-H$3:)99,=2K\E2 M*F(!M,50JJD83ZR.E8)7L4B.+Y*"98D&GPXB:6&NFO89+FQ9T#CR(M@ @RCZ MB+<=8N0DA.D\$B4I#&IHML$WVDHDH-PID-+4=9.@%C[DSO0-SBQCQ*I0%)I MTA:\#S#J5X_SD%BF8:6Q [JAI(#Z MJ$@]++;[LBI L7*GC<4Z8F*9)1UG0ZY6]Y^D7K1:6%@P,'#1D0:/BW%ONW<# MU_DRL I)'!FF93RV YAQ"3Z>@_T@;=>7D6!;OS8;PX0W6>F(QY,=M%S5I8V" MN;B3B1R6V4^L:0D.7.;YD8CZ%A4JE0VQ^9=:2AB&U M<9%10J.2%RQWC17X3AE"0*]XA X-9KU!D8-:WTD\%:4J$D<$/8P@ FT@=0PC MS5$[?G(N;"9](%MA:A_&+Y+=<:!8&?7_5DZ=IGF7TSYW=>]J/(H^OJT=10^C M*VH>4'62F010G!Y<0MMDDO!(>M0*N5B\2J]'[F"^H& ]O M"&/*+0,]"P/'+Q;;>0ADA+M;"H2M%]?K5:7-IZC2CVFJ9NI8RRR'_1#93^O- M=TI1O5$HWNC[#59V]?#RAVI7>X1VM?>KQX2GU_W"-U9\H?83\;PYI[Y7B_UE MCGUO$,%OUR*L-/G[/TR[K"!#_0,>UG[%*ZUN6!]^+>BTH>MU/%V)TRWN>"-4 L+T MV2=,G>RS$74'2?Z2/FR@*^!6:H094ZH[T)4C7P":YD_ ?L?5*>MS9K9A INU M0;-J:ZU^:-16_%K]9OG6U=>SA!LUXW#NKLP5!_57JL#./G6_="YNR$VG_>O% MY9?+3]U.KT2Z%^TBNW9'RCM2?ENXW1'NCG#?)&Y72K@Y&GU>?L&VX7LU*#XT MFL]^$>-M8_C#I+5*]#XL>H^><^7_V\9W15;(E4'.X3/%VWRBG19\HY+C 7QJ M<;)-Z,2+M]8N.N#_1N>M+\>;SK;';,%"*B8[*;B3@F\#DY,5\T-"YH=&W56VM3&SL2_7ZK]C_HDMTLU-IC&T@"AJ6N M,22P"80")ZGLERW-3-NCBT::*VGL>'_]=FL>#*\\N-ED(%4!QAJI^_3IAUIB M]]>#M^/)Q[-#=C0Y>X>D*6TFW_Y99>>^>_ M8_KNA). /_ N?-K>'OQG-_;7;9:>OV%BK.1@'ALV?!?U@ M/7C69]TN#0AUO,3OO^QFS+JEA'^N./CDNER*F1H:,4O<3LK-3*ANJ)W3Z;"? MU4^"KD%@ M@%,4OY( 0Z5-RF4QJ2/8IO@ GRHH1LVY$1Q78N7 E;W#3XD(A6/;V\%@MY?M M?7=E2MDG(@7+3F'!SG7*U4T=5O:>JM!F._>+$.&D8';V>70Y,SI7<3?24IOA MDY?^Z\\C74ZWX;^:\FU6&-]IA@?B?F "=B(N.4AVH*5UH-@I3R%F3K/13$B4 MDNUK;F*FI^Q &(B<-O9[P3-8_R(^]\*Q_CDX2D!+-?\40F=37,XP^ 11[L0< M&"ZB9A9U-UK-F(T$2BJF(F)2@ %Z/3R8B-WXS.1QU&,TZ##KN S 5L?:/#UOOK@UUZM=+H#@.L[+&G3[;6 M!X.=&HL)1(E"V\X$V X[5E' 5D\_7AP.V6@-,8OY$O%4R*"(R)APQVY3M<.B M1,"T:0,]Q?_17&2+S( 5!%N'?=!&Q@O\A9V#!6ZBI,,.8 Y29RE)0\-/"M-U M6&EQ+U/"+0L!O0(D4O^:7WB-7NS8PJSD'W'E'QT&TRG^2'0ID1H42 6[/<)G M[[NPX,X*DM[)UP1,]6N*?: #U7;(")+T*#B9@[8+')41 ?=?RT.49U M%DFAO!M:E\=(,(;*>5F< >Z\Q?$!\F-.O-&*Y"_>C-%E.7HM$:*VO5!S+>.W)\?GIZ/)QZ=/!B\V=]CJ M^.W[XX/N8+N2HL-2_'PM>(1T(TC6^SN%Q]?XZ-Q91\:_%GH[==PE"YC2Q5E8 M9R&6\DLT22)2QA$;F?-0HI'CV-=S=S*UXP7 B&6YB"GP #N)3G(I*>Y4(^L0 MXQ<>'[X-6"GWD2!"\QB,341&S+&HE^RF&@F=X^)>8B)*AX5"X_*&9X 9)L(' M,U!$+7I$[+U&JX60$FF)>EP"QDAKP7EZ5R*E>D[@X*.%][D*X+ M;2YIC.=5&5)IC1"7G0KG_/M&I]Y)&PZ-2J!0Z!V8^]#W9H2X7#*19MJ@41 $ M="\;E, ]7LY]@))OZ."9I'A0P 8RTBE4B'V9-*\UNJU&?ATM "A9<6$HU-P1 M%1NLB0&R)G41]3*VDHUL'D5@[32737KAI)%!+I,+U/3'&.@$IR2$%')56O/\ M0>;C; W+H8UM5F8L5$SGQK.$WBLE?<1F;68N"NH63!7-&8T&MR0$#;IFD2I* MJ*P@UJ_W^]LX-I*YCSKWE1R=1C# R+@NU3?40;7V@^T.6Z! 0%F+ M.(=L\GF:)M2X)V5;G7Z_7T%B71&PZ!,+1#WDVTSJL$E-C7SSN0T_CHRVJ(3X MQ!IJ%Z&D88P Z[$Z8'=8?+N*N-_*];(-C\ETL96A%#:Y M574U]SJXN8EDF9M"RB]83 E8% \$?4/+^G!2@%XFC^8<&$S3'&/4TC.YY"WF M$V\X2]S%&NE:T#SE1?L%K6&=<+D#7WH> 9=HOKL!)W2;:#=VYM^G3T!M'5,M MFO$9=$/D[F673[$F'7*YX$N[@S[GDN&@C\NLW,^*']'+^#(/?P+Q;F\@?^SZ MJZ?'1VO5UNPGR])MB1RCELB!]8[TV0+C?4M$.FF)'.46HB72V);(T1:6G+5$ M#LS5JJAZ6B(0UJ1Z9GC:%G&H9,%ZY:K%2Y4)[H.!=NEI"%?UQ_%16\@U:H;% MNNTS:530Q]03*QM<15GVONHAK([&D^/W:VW1Y6JCBLAK@]NL0BW.5%7P^;(Q MJCL/2RPG6R(\[2XR1)CVS6T1J>)#2^0)VD*TQA:Q)1+A[MBVAC;EQDL7.[6+ MTN4H3;C>QCGA*I_B_C@W4)R> MC%(P.(RMGB7G)Z,U/\CY2?!7]I(:@<59P.W#V-9X%V[B6R))=7+3$G'0FFV1 MI"5R"!7GF,J7-^JK5]0T5-2)[+Y3@AJ(PBV[Q]7@VH7.R1^ RI[XX?JAG6CL4I:YD:&J'G\?4Z[VD7\Z)U&<^%I3/CXHSG;?U>WW?VE@^_1CU0H=]UPB_H@F^X2L%.RF&".(F"ISX(X_J MM#N&F8&"+;$FM.A&A#^Y?4,GAU[UT=]4@QA49(C 6?*6U+GZ5V2Y9)@92+$D@]E5'W2W T%"2Q MEM*,4)94*8Z4E-)S7M[6\!<91$J7:V@<>?X?.6)0G./2VD%M 9S$F9R")TYN M]=3AR]#QX5YXV:R6N>^1%))EH#-)Y[0X=TPWAK#V(-]0=D&U.D;E")]HK-?M MWUE*UWJBA-.MD!F)\D<.UD\6^&P:Z33C:NDO=)!STN64.:C<;YG^^BS8V&2A MD)*T0M"FPA(4=*6* GS?RP-I)O72LL'SSF:_7XFWJ YRZ5R4[%A PZ^1CTPS MYT(6EUT!K$$)67C(;H:F DIOCJRF7_V?.-\0!90->;>7D) !4J4SXJ MJ*O0Y"V >1!UKQ=7L$!$B^L3S.:AC8P(;UT*>Z!(ISBYT0U97FHI]:*>%J%X MX,QOA+J$^+@JV#L/G6>RH*VQJ:XB:0CUEK9+UZ_?02AY0DK_WV/ M=/(CXSM=C^!T&]_A_GWX^"J+"58'^UC'IURIQR?]/P9LL[_%-K:>LV=;V^N/ M3X&OC $K>ZA!$)9V^NUV^/U)EQUV>^5?F^SVRK]I^1]02P$"% ,4 " "X M@C=3.U9D?*X$ !5%@ #@ @ $ 82TR,#(Q,#DR,2YX M&UL4$L! A0#% @ N((W4VP<)J[R! M22L !( ( !%PP &$M,C R,3 Y,C%?<')E+GAM;%!+ 0(4 M Q0 ( +B"-U,96UW9_!< $[3 1 " 3D1 !A+3AK M7S(P,C$P.3(Q+FAT;5!+ 0(4 Q0 ( +B"-U.N._WEF H $0S . M " 60I !A+65X.3DQ7S0T+FAT;5!+!08 !0 % #